FDA, EMA ad­vise on risk-based mon­i­tor­ing in clin­i­cal tri­als

US and EU of­fi­cials ex­plained on Wednes­day what their re­spec­tive reg­u­la­to­ry agen­cies look for in clin­i­cal tri­al risk-based mon­i­tor­ing (RBM) and how RBM can im­pact re­view times.

Un­der a co­op­er­a­tive agree­ment with the FDA, the Duke-Mar­go­lis Health Pol­i­cy Cen­ter con­vened the pub­lic work­shop in Wash­ing­ton, DC for a de­bate on im­prov­ing the im­ple­men­ta­tion of RBM in clin­i­cal tri­als by iden­ti­fy­ing how reg­u­la­tors can help with some of the cur­rent bar­ri­ers to wide­spread adop­tion of RBM. Par­tic­i­pants looked for clar­i­fi­ca­tion around how reg­u­la­tors’ ap­proach­es to RBM dif­fer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER